AnPac Bio-Medical Science Co., Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Chris Chang Yu
- Full Time Employees
- 89
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 801 Bixing Street Lishui People's Republic of China 323006
- IPO Date
- Jan 30, 2020
- CIK
- 0001786511
- Website
- anpacbio.com
- Similar Companies
- Business
- AnPac Bio-Medical Science Co., Ltd. is a biotechnology company primarily engaged in the development, manufacturing, and commercialization of advanced diagnostic products and services. Its core products include next-generation sequencing (NGS) platforms, genetic testing kits, molecular diagnostics, bioinformatics solutions, and precision oncology services. The company specializes in cancer risk assessment, early tumor detection, and personalized medicine solutions, serving healthcare providers, research institutions, and diagnostic laboratories. It operates primarily in China with expanding markets globally. Founded in 2016 and headquartered in Beijing, AnPac Bio-Medical Science Co., Ltd. leverages cutting-edge technology to provide comprehensive cancer risk assessment and early diagnosis products to enhance clinical outcomes. In the last 1-2 years, the company has made significant strategic advancements including partnerships with major healthcare and research institutions to broaden its product reach and enhance technological capabilities. It has launched novel products in liquid biopsy and multi-cancer early detection, reflecting a major business expansion into broader precision oncology solutions. These developments include enhancement of its big data and AI-driven bioinformatics platforms to improve diagnostic accuracy and clinical applicability. The company continues to focus on strengthening its market presence and operational scale within China and internationally, further solidifying its leadership in the molecular diagnostics and precision medicine sectors. AnPac’s recent moves also include new strategic collaborations and possible funding rounds aimed at technological innovation and global market penetration. AnPac Bio-Medical Science Co., Ltd. serves the biotechnology and healthcare industry segments focusing on molecular diagnostics and precision oncology. Its target customers include hospitals, research laboratories, and health screening centers, addressing the growing demand for genomics-based cancer diagnostics and personalized medicine. Operating out of Beijing, it stands as a prominent player in China’s biotech sector with an increasing footprint in Asia and potential global markets. The company remains privately held with a focus on innovation-driven growth and expansion in diagnostics technology offerings.
10 Top Penny Stocks To Buy For Uner $1 Right Now
Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week
Cheap Penny Stocks to Buy in September? 3 For Your List
AnPac Bio-Medical Science (ANPC) Stock Surges 66.01%: Details
Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public
What to Know About Buying Penny Stocks on May 12th
Popular Penny Stocks to Buy in April? 3 to Watch Right Now
Best Penny Stocks To Buy? 5 China Stocks To Watch Right Now
5 Penny Stocks Under $1 To Buy According To Redditors This Week
AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases
AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3%
AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Deficiency
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase In Subsidiary Holding
AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%
AnPac Bio's USA Laboratory Receives Accreditation from the College of American Pathologists
AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device
AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO
AnPac Bio Announces Appointment of New Independent Director
AnPac Bio Began Generating Contract Medical Device R&D Revenue
AnPac Bio Stock Gains On Robust Growth In Commercial Testing Volume In Q2